TY - JOUR
T1 - Investigating Potential Adverse Drug Reactions of Lisdexamfetamine Using Sequence Symmetry Analysis
AU - Jensen, Thomas Leth
AU - Thysen, Sanne Moller
AU - Jimenez-Solem, Espen
AU - Jorgensen, Anders
AU - Jensen, Camilla Bjorn
AU - Raket, Hans Kristian
AU - Osler, Merete
AU - Nielsen, Mads
AU - Lund, Lars Christian
PY - 2026
Y1 - 2026
N2 - The prevalence of ADHD is increasing rapidly, and lisdexamfetamine is increasingly popular, but few studies investigate its safety. We performed a sequence symmetry analysis (SSA) using Danish register data to identify potential ADRs associated with lisdexamfetamine in 2013-2023. Outcomes were incident prescriptions or incident discharge diagnoses. We calculated trend-adjusted sequence ratios (SR) with 95% confidence intervals (CI). We additionally performed two comparator SSAs for the same outcomes following incident use of stimulants (methylphenidate and dexamfetamine) or non-stimulants (guanfacine and atomoxetine). This study is reported according to RECORD-PE guidelines. We included 48 740 incident lisdexamfetamine users with a median age of 24 years (IQR 16-35). SRs were calculated for 1426 exposure-diagnosis and 1337 exposure-prescription pairs. The 50 highest SRs from each category were evaluated. Among these, 28 exposure-outcome combinations had a 95% CI lower bound above 1. Of the 100 outcomes, 33 were considered known ADRs, while 60 were previously unknown. Two outcomes indicating increased urinary symptoms were identified ('hematuria', SR: 1.88 [95% CI: 1.25; 2.85] and 'other urinary symptoms', SR: 1.63 [1.20; 2.23]). We also identified serious gastrointestinal outcomes as a potential safety alert. Further investigation into these symptoms as potential ADRs is warranted.
AB - The prevalence of ADHD is increasing rapidly, and lisdexamfetamine is increasingly popular, but few studies investigate its safety. We performed a sequence symmetry analysis (SSA) using Danish register data to identify potential ADRs associated with lisdexamfetamine in 2013-2023. Outcomes were incident prescriptions or incident discharge diagnoses. We calculated trend-adjusted sequence ratios (SR) with 95% confidence intervals (CI). We additionally performed two comparator SSAs for the same outcomes following incident use of stimulants (methylphenidate and dexamfetamine) or non-stimulants (guanfacine and atomoxetine). This study is reported according to RECORD-PE guidelines. We included 48 740 incident lisdexamfetamine users with a median age of 24 years (IQR 16-35). SRs were calculated for 1426 exposure-diagnosis and 1337 exposure-prescription pairs. The 50 highest SRs from each category were evaluated. Among these, 28 exposure-outcome combinations had a 95% CI lower bound above 1. Of the 100 outcomes, 33 were considered known ADRs, while 60 were previously unknown. Two outcomes indicating increased urinary symptoms were identified ('hematuria', SR: 1.88 [95% CI: 1.25; 2.85] and 'other urinary symptoms', SR: 1.63 [1.20; 2.23]). We also identified serious gastrointestinal outcomes as a potential safety alert. Further investigation into these symptoms as potential ADRs is warranted.
KW - ADHD medication
KW - Adverse drug reactions
KW - Lisdexamfetamine
KW - Pharmacovigilance
KW - Sequence symmetry analysis
U2 - 10.1111/bcpt.70316
DO - 10.1111/bcpt.70316
M3 - Journal article
C2 - 42847833
SN - 1742-7835
VL - 139
JO - Basic & clinical pharmacology & toxicology
JF - Basic & clinical pharmacology & toxicology
IS - 5
M1 - e70316
ER -